Stock Expert AI
Northrop Grumman Corporation
NOC - NYSE - $549.22 ▲ +%0.30
-
Earnings Tue 20 Oct

Northrop opens the
books on Tuesday evening.

8 analysts' median target is $620[FMP target], stock is $549, +12.9% upside potential. After Q2 +12.6% EPS beat[FMP earnings], the stock moved +2.5%.

summary below
Quick Take - in 40 seconds
A-
HOLD Council 3/6 - Moonshot 44

A- = MoonshotScore 44[multi-pillar formula] + Council 3/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q1 consensus: revenue $11.1B[FMP est], EPS $7.13[FMP est]. 5 consecutive quarters of beat[FMP earnings].

$7.13 EPS Estimate Last year $6.14 - -7% YoY YoY
5 Beat Streak Expectations beaten consecutively for the last 5 quarters

Q2 EPS +12.6% beat[FMP] but the stock +2.5% D+1[FMP D+1]. John Greene promised $302.0M CapEx + a sequential decline in Q1 during the Q2 earnings call[John Greene capex transcript].

Watchlist

6 metrics stand out this quarter.

2026 Expectation / Guide

Fy26 Sales Eps Guidance

fy26_sales_eps_guidance

The company raised its FY2026 sales guidance to a midpoint of $44 billion, representing over 5% organic growth, and increased EPS estimates by $1.20, driven by strong Q2 results and accelerating momentum.

"Based on our strong Q2 results and accelerating momentum, we are increasing our financial guidance for 2026. Robust bookings are continuing, and we now expect a full year book-to-bill ratio of at least 1.25 times. Sales are now projected at $44 billion at the midpoint, which is over 5% organic growth. We are maintaining our expectations for segment margin performance, and we raised EPS estimates by $1.20."

- Kathy Warden, Chair, CEO, and President - Q2 FY26 Earnings Call - July 21, 2026
$1.85 billion Risk Indicator

Capex Production Capacity

capex_production_capacity

Northrop Grumman plans continued infrastructure investments, expecting $1.85 billion in CapEx for 2026 and around 4.5% of sales in 2027 and 2028 to support the B-21 production ramp.

"We continue to expect $1.85 billion of CapEx in 2026. As we previously shared, we expect CapEx investments of around 4.5% of sales in 2027 and 2028 as we invest in infrastructure to support the B-21 production ramp."

- John Greene, CFO - Q2 FY26 Earnings Call - July 21, 2026
$20 billion Investor Focus

Record Backlog Book To Bill

record_backlog_book_to_bill

Northrop Grumman achieved a record high backlog of $105 billion and expects a full year book-to-bill ratio of at least 1.25x, driven by strong Q2 results and accelerating momentum.

"We delivered $20 billion in net awards in the quarter, driving a book-to-bill ratio of 1.84 times. Backlog continues to grow, including a new record high of $105 billion. We expect continued strong bookings for the remainder of the year, as well as increased momentum in government outlays. These dynamics strengthen our confidence and outlook for accelerating sales growth in the second half of the year. ... Robust bookings are continuing, and we now expect a full year book-to-bill ratio of at least 1.25 times."

- Kathy Warden, Chair, CEO, and President - Q2 FY26 Earnings Call - July 21, 2026
$2 billion Investor Focus

Tactical Missile Strategy

tactical_missile_strategy

The company is strengthening its tactical missile strategy by qualifying as a supplier for PAC-3 and securing a $2 billion framework agreement with the DoD, with 10 multi-year missile acceleration agreements offering up to $10 billion in sales opportunities over the next seven years.

"Last month, we completed qualification activities to become a supplier on PAC-3, and we reached a $2 billion framework agreement with the Department of Defense and Lockheed Martin. We expect the PAC-3 SRM production award later this year. In total, we have 10 multi-year agreements for missile acceleration in work across the portfolio with up to $10 billion of sales opportunity over the next seven years."

- Kathy Warden, Chair, CEO, and President - Q2 FY26 Earnings Call - July 21, 2026
$7.6 billion Investor Focus

Sentinel Program Progress

sentinel_program_progress

The Sentinel program achieved significant progress, adding $7.6 billion to the program backlog and expecting the first flight of the integrated missile in 2027.

"We continue to make progress on the Sentinel program in partnership with the Air Force. This led to further definitization and authorization for us to execute additional elements of the program plan, resulting in a $7.6 billion increase in program backlog. During the second quarter, we achieved contract incentives, which improved overall profitability and delivered program milestones as scheduled. ... first flight of the integrated missile, which is expected in 2027."

- Kathy Warden, Chair, CEO, and President - Q2 FY26 Earnings Call - July 21, 2026
$50 billion Investor Focus

International Demand Wins

international_demand_wins

Northrop Grumman is capitalizing on increased global defense spending with significant international agreements, including Triton aircraft for NATO, IBCS systems for Kuwait, and a solid rocket motor manufacturing facility in Australia.

"At the NATO summit a few weeks ago, our allies pledged $50 billion in additional investments, including a commitment for Northrop Grumman's Triton autonomous aircraft. In the Middle East, modern missile defense systems remain an essential priority for ensuring national security. Momentum continues to build in numerous countries to acquire our IBCS system, which is proven and operational today. This includes Kuwait, who in May received authorization from the State Department for six IBCS systems. In Australia, we were selected to establish an in-country solid rocket motor manufacturing facility."

- Kathy Warden, Chair, CEO, and President - Q2 FY26 Earnings Call - July 21, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 3 / 6 Bullish

6 investor frameworks. 3 bullish (Ray Dalio, Ken Griffin, Buffett), 0 bearish (none), 3 neutral (Jim Simons, Klarman, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +12.9%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 58
Klarman value - target upside +12.9%
Buffett quality - ROE score 5/5
Munger valuation - target upside +12.9%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthStrong
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
58.0 RSI 58.0 positive momentum, 50d above
MACD
+2.40 price above 50d - support positive
50d MA
$536 stock 2.4% above - short-term support
200d MA
$608 stock 9.6% below - long-term pressure
Volume (10d)
-34% decrease - low participation
Resistance
$620
Analyst median target - upgrade trigger if broken
Current
$549
Pre-earnings position
Support
$517
Invalidation - close below this is a technical breakdown
Pattern
Range
$517-$620 band - earnings breakout/breakdown trigger

Past Performance

Northrop's last 8 quarters: 5 consecutive beats.

BEAT
Q3 FY25
$7.67 vs $6.44 est - -0.5%
BEAT
Q4 FY25
$7.23 vs $6.98 est - +1.5%
BEAT
Q1 FY26
$6.14 vs $6.06 est - -3.5%
BEAT
Q2 FY26
$7.68 vs $6.82 est - +2.5%

Q2 (July 21, 2026): EPS $7.68 vs $6.82 est[FMP], +12.6% beat. D+1 movement: +2.5%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $6.92 (no guidance)

Q2: EPS $7.68 vs $6.82 beat[FMP], stock +2.5% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q2 earnings call.

CapEx shock

Q2 CapEx $302.0M[FMP cashflow]. Q2 op margin 10.1%[FMP op margin] - this level in Q1 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q1 EPS > $7.13 + CapEx discipline
Threshold: EPS > $7.13[FMP est].
Target: Break above median target $620[FMP target]; high target $785[FMP] upper bound.
Scenario B - In-Line
EPS approx $7.13 + CapEx < $302.0M
Threshold: EPS approx $7.13[FMP est], Q1 CapEx < $302.0M[FMP].
Target: Consolidation in the band between current $549[FMP] and median $620[FMP].
Scenario C - Miss
EPS < $6.92 or CapEx >= $302.0M
Threshold: EPS < $6.92[FMP estx0.97].
Target: Current $549 below SMA200 $608[FMP], if rejection continues, $517[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 8 analysts say?

Wall Street Consensus
$620
12-month median target price (+12.9% upside potential)
14
BUY
9
HOLD
0
SELL
Risk Management
$517
Invalidation level - critical support threshold
$536 - 50-day MA (above, +2.4%)
$608 - 200-day MA (below, -9.6%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - NOC Q1 FY27
A-

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q1 EPS threshold $7.13[FMP], CapEx threshold "below $302.0M"[John Greene]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Oct 20, 2026EARNINGSQ1 FY27 results (after market close) + earnings call
Oct 21, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Dec 4, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Jan 20, 2027EARNINGSQ2 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the NOC earnings preview cover?

This Northrop Grumman Corporation (NOC) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in NOC earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded